"name","description","instanceType","uuid:ID","id","label","rationale"
"Study Design 1","The main design for the study","StudyDesign","4d77b4d8-2922-4a02-a2cc-03d3e4d980fe","StudyDesign_1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
